Eli Lilly's profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker debuted a mostly better-than-expected 2025 forecast.

Eli Lilly (LLY) came out with quarterly earnings of $5.32 per share, beating the Zacks Consensus Estimate of $5.03 per share. This compares to earnings of $2.49 per share a year ago. These figures are ...

Eli Lilly earnings topped Q4 views with 2025 guidance above consensus, even though Zepbound and Mounjaro slightly missed. Eli Lilly stock rose.

The Washington University trial comes as part of a larger platform study which hopes to understand if Alzheimer's disease can ...

UnitedHealth Group, AbbVie, and Eli Lilly and Company are the three Medical stocks to watch today, according to MarketBeat’s stock screener tool. Medical stocks refer to equities in companies that are ...

Eli Lilly stock rose after the drugmaker posted quarterly earnings that beat Wall Street expectations, and issued upbeat 2025 guidance. Fourth-quarter adjusted earnings came in at $5.32 a share, above ...

Eli Lilly has expanded a collaboration with ... against rivals such as Apple and FitBit whose wearable devices have an increasing medical focus with tech like ECG readers. ActiGraph provides ...

Jan 13 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the main ingredient in its popular ...

That’s how much Eli Lilly’s revenue grew in 2024, but it was still not as much as the company or investors expected, which had CEO David Ricks trying to assuage investors. Lilly on Tuesday ...

Eli Lilly's operational performance is strong, but shares are expensive, leading me to reaffirm a 'hold' rating despite potential upside from new drugs. Recent financial results show significant ...